Drug discovery in academia: the third way?

Julie Frearson, Paul Wyatt

    Research output: Contribution to journalReview article

    29 Citations (Scopus)

    Abstract

    As the pharmaceutical industry continues to re-strategise and focus on low-risk, relatively short-term gains for the sake of survival, we need to re-invigorate the early stages of drug discovery and rebalance efforts towards novel modes of action therapeutics and neglected genetic and tropical diseases. Academic drug discovery is one model which offers the promise of new approaches and an alternative organisational culture for drug discovery as it attempts to apply academic innovation and thought processes to the challenge of discovering drugs in addressing real unmet need.

    Original languageEnglish
    Pages (from-to)909-919
    Number of pages11
    JournalExpert Opinion on Drug Discovery
    Volume5
    Issue number10
    DOIs
    Publication statusPublished - Oct 2010

    Keywords

    • academia
    • drug discovery
    • neglected disease
    • novel targets
    • RESEARCH-AND-DEVELOPMENT
    • OPEN INNOVATION
    • INDUSTRY

    Cite this